BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rensel M. Long-Term Treatment Strategies of Pediatric Multiple Sclerosis, Including the use of Disease Modifying Therapies. Children (Basel) 2019;6:E73. [PMID: 31159312 DOI: 10.3390/children6060073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Greene N, Araujo L, Campos C, Dalglish H, Gibbs S, Yermilov I. The Economic and Humanistic Burden of Pediatric-Onset Multiple Sclerosis. Journal of Health Economics and Outcomes Research 2022;9. [DOI: 10.36469/001c.37992] [Reference Citation Analysis]
2 Yüksel Yilmaz D, Yardimci F. Retrospective Evaluation of Demographic and Clinical Characteristics of Children with Multiple Sclerosis. KOU Sag Bil Derg 2022;8:139-143. [DOI: 10.30934/kusbed.1060124] [Reference Citation Analysis]
3 Greene N, Araujo L, Campos C, Dalglish H, Gibbs S, Yermilov I. The Economic and Humanistic Burden of Pediatric-Onset Multiple Sclerosis. JHEOR 2022. [DOI: 10.36469/jheor.2022.37992] [Reference Citation Analysis]
4 Куликова С, Кузнецова А, Лихачев С, Голец Ю. Pediatric Multiple Sclerosis: Diagnostics and Treatment (Review). Неврология и нейрохирургия. Восточная Европа 2021. [DOI: 10.34883/pi.2021.11.1.034] [Reference Citation Analysis]
5 Jure Hunt D, Traboulsee A. Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic. Mult Scler J Exp Transl Clin 2020;6:2055217320926613. [PMID: 32655877 DOI: 10.1177/2055217320926613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Ziemssen T, Kern R, Voigt I, Haase R. Data Collection in Multiple Sclerosis: The MSDS Approach. Front Neurol 2020;11:445. [PMID: 32612566 DOI: 10.3389/fneur.2020.00445] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]